(QTRX) Quanterix - NASDAQ
Sector: Healthcare | Industry: Medical Devices | Exchange: NASDAQ (USA) | Market Cap: 155m USD | Total Return: -54.5% in 12m
Avg Turnover: 2.53M
Qual. Beats: 1
Rev. Trend: 85.1%
Qual. Beats: 0
Warnings
Share dilution 21.3% YoY
Beneish M-Score -0.19 > -1.5 - likely earnings manipulation
Altman Z'' -1.31 < 1.0 - financial distress zone
Tailwinds
No distinct edge detected
Quanterix Corporation (QTRX) is a life sciences company specializing in high-sensitivity protein analysis. The firm develops and markets the Simoa (Single Molecule Array) platform, which includes the HD-X, SR-X, and SP-X instruments. These technologies enable researchers to detect biomarkers at concentrations significantly lower than traditional enzyme-linked immunosorbent assays (ELISA). The company operates within the Life Sciences Tools & Services sector, a capital-intensive industry where revenue is typically driven by a razor-razorblade model involving initial instrument placement followed by recurring sales of proprietary consumables and assays.
The company’s product portfolio includes complete assay kits, reagents, and replacement parts. Beyond hardware, Quanterix provides contract research and clinical laboratory testing services through its Accelerator Laboratory. Its primary market focus includes neurology, oncology, and immunology, serving academic institutions, government agencies, and pharmaceutical companies. For a deeper look into the companys valuation metrics and historical performance, consider reviewing the data on ValueRay. Founded in 2007 and headquartered in Billerica, Massachusetts, the company serves a global market across North America, Europe, and the Asia Pacific.
- Alzheimer’s drug approvals drive demand for high-sensitivity p-tau blood biomarker testing
- Expansion of Simoa platform placements increases recurring consumable and reagent revenue
- Clinical laboratory services growth hinges on pharmaceutical partnership and trial volume
- High research and development spend delays transition to sustained GAAP profitability
- Regulatory shifts in LDT oversight impact diagnostic laboratory service revenue streams
| Net Income: -104.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.23 > 0.02 and ΔFCF/TA -14.28 > 1.0 |
| NWC/Revenue: 93.75% < 20% (prev 220.0%; Δ -126.2% < -1%) |
| CFO/TA -0.22 > 3% & CFO -81.5m > Net Income -104.2m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.72 > 1.5 & < 3 |
| Outstanding Shares: last quarter (47.0m) vs 12m ago 21.34% < -2% |
| Gross Margin: 44.18% > 18% (prev 59.14%; Δ -14.96% > 0.5%) |
| Asset Turnover: 37.97% > 50% (prev 33.77%; Δ 4.19% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.37 (Total Current Assets 185.7m - Total Current Liabilities 49.9m) / Total Assets 366.7m |
| B: -1.62 (Retained Earnings -594.8m / Total Assets 366.7m) |
| C: -0.29 (EBIT TTM -110.8m / Avg Total Assets 381.6m) |
| D: 3.34 (Book Value of Equity 282.1m / Total Liabilities 84.5m) |
| Altman-Z'' = -1.31 = CCC |
| DSRI: 0.88 (Receivables 26.8m/28.3m, Revenue 144.9m/133.9m) |
| GMI: 1.34 (GM 59.14% / 44.18%) |
| AQI: 5.34 (AQ_t 0.39 / AQ_t-1 0.07) |
| SGI: 1.08 (Revenue 144.9m / 133.9m) |
| TATA: -0.06 (NI -104.2m - CFO -81.5m) / TA 366.7m) |
| Beneish M = -0.19 (Cap -4..+1) = D |
As of June 12, 2026, the stock is trading at USD 3.03 with a total of 627,302 shares traded.
Over the past week, the price has changed by -20.26%,
over one month by +8.21%,
over three months by -39.52% and
over the past year by -54.50%.
Quanterix has received a consensus analysts rating of 3.75. Therefore, it is recommended to hold QTRX.
- StrongBuy: 1
- Buy: 1
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 4.3 | 42.9% |
P/S = 1.0722
P/B = 0.6344
Revenue TTM = 144.9m USD
EBIT TTM = -110.8m USD
EBITDA TTM = -89.7m USD
Long Term Debt = 27.4m USD (estimated: total debt 35.3m - short term 7.93m)
Short Term Debt = 7.93m USD (from shortTermDebt, last quarter)
Debt = 35.3m USD (from shortLongTermDebtTotal, last quarter) (leases 35.3m already included)
Net Debt = -63.9m USD (calculated: Debt 35.3m - CCE 99.3m)
Enterprise Value = 91.5m USD (155.4m + Debt 35.3m - CCE 99.3m)
Interest Coverage Ratio = unknown (Ebit TTM -110.8m / Interest Expense TTM 0.0)
EV/FCF = -1.10x (Enterprise Value 91.5m / FCF TTM -82.9m)
FCF Yield = -90.58% (FCF TTM -82.9m / Enterprise Value 91.5m)
FCF Margin = -57.22% (FCF TTM -82.9m / Revenue TTM 144.9m)
Net Margin = -71.92% (Net Income TTM -104.2m / Revenue TTM 144.9m)
Gross Margin = 44.18% ((Revenue TTM 144.9m - Cost of Revenue TTM 80.9m) / Revenue TTM)
Gross Margin QoQ = 42.75% (prev 45.69%)
Tobins Q-Ratio = 0.25 (Enterprise Value 91.5m / Total Assets 366.7m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 35.3m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -87.5m (EBIT -110.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.72 (Total Current Assets 185.7m / Total Current Liabilities 49.9m)
Debt / Equity = 0.13 (Debt 35.3m / totalStockholderEquity, last quarter 282.1m)
Debt / EBITDA = 0.71 (negative EBITDA) (Net Debt -63.9m / EBITDA -89.7m)
Debt / FCF = 0.77 (negative FCF - burning cash) (Net Debt -63.9m / FCF TTM -82.9m)
Total Stockholder Equity = 296.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -27.30% (Net Income -104.2m / Total Assets 366.7m)
RoE = -35.17% (Net Income TTM -104.2m / Total Stockholder Equity 296.2m)
RoCE = -34.24% (EBIT -110.8m / Capital Employed (Equity 296.2m + L.T.Debt 27.4m))
RoIC = -27.58% (negative operating profit) (NOPAT -87.5m / Invested Capital 317.5m)
WACC = 8.51% (E(155.4m)/V(190.8m) * Re(10.44%) + D(35.3m)/V(190.8m) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 10.44% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 10.03%
[DCF] Fair Price = unknown (Cash Flow -82.9m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 4.0 | # QB: 1
Revenue Correlation: 85.12 | Revenue CAGR: 7.40% | SUE: -0.14 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.40 | Chg30d=+3.22% | Revisions=+20% | Analysts=3
EPS next Quarter (2026-09-30): EPS=-0.29 | Chg30d=+20.36% | Revisions=+20% | Analysts=3
EPS current Year (2026-12-31): EPS=-1.23 | Chg30d=+40.87% | Revisions=-20% | GrowthEPS=+0.0% | GrowthRev=+22.3%
EPS next Year (2027-12-31): EPS=-1.36 | Chg30d=+28.80% | Revisions=-20% | GrowthEPS=-10.6% | GrowthRev=+11.0%
[Analyst] Revisions Ratio: +20%